Therefore, the combined assessment of ctDNAs and AFP may improve HCC detection, exceeding the previously described plasma biomarkers, in terms of higher sensitivity and better clinical correlation in discriminating HCC patients from the normal controls [188]. Here, AFP is linked to hepatocellular carcinoma.